Drug Overview
Flutiform ([fluticasone propionate + formoterol fumarate]; Vectura/Mundipharma/Kyorin) is a pressurized metered-dose inhaler formulation which contains a combination of fluticasone propionate and formoterol. Fluticasone propionate is an inhaled corticosteroid which has potent anti-inflammatory activity when delivered by inhalation, while formoterol fumarate is a long-acting beta 2 agonist which acts as a bronchodilator.
Flutiform ([fluticasone propionate + formoterol fumarate]; Vectura/Mundipharma/Kyorin) is a pressurized metered-dose inhaler formulation which contains a combination of fluticasone propionate and formoterol. Fluticasone propionate is an inhaled corticosteroid which has potent anti-inflammatory activity when delivered by inhalation, while formoterol fumarate is a long-acting beta 2 agonist which acts as a bronchodilator.
Table of Contents
1 Product Profiles- Flutiform: Asthma
List of Figures
Figure 1: Asthma - current and future market dynamics analysis
Figure 2: The author’s drug assessment summary of Flutiform in asthma
Figure 3: The author’s drug assessment summary of Flutiform in asthma
List of Tables
Table 1: Flutiform drug profile
Table 2: Flutiform pivotal trial data in asthma
Table 3: Flutiform Phase III trials in asthma
Table 4: Flutiform sales for asthma across Japan and the five major EU markets, by country ($m), 2017-26
Companies Mentioned
- Vectura
- Mundipharma
- Kyorin
